Abstract:One of the neuropathological hallmarks of Alzheimer's disease is the presence of β-amyloid (Aβ)-containing neuritic plaques. Aβ is produced by the proteolytic cleavage of the amyloid precursor protein by β- and γ-secretase enzymes. Thus, inhibition of β-secretase (BACE1) is a promising disease modifying approach for the treatment of Alzheimer's disease. Identification of orally-bioavailable, CNS-active small molecule BACE inhibitors is challenging. SCH 785532 is a novel, potent, non-peptidic, orally available and brain penetrant BACE inhibitor. Following acute administration in pre-plaque transgenic CRND8 (TgCRND8) mice over-expressing human amyloid precursor protein with two familial Alzheimer's disease mutations, SCH 785532 produced robust inhibition of plasma Aβ but only modestly reduced cortical Aβ levels. This study sought to determine if chronic treatment with this BACE inhibitor would reduce cortical Aβ levels as well as to assess the disease modifying potential of chronic BACE inhibition as measured by a reduction in plaque deposition and/or improvement in cognitive performance. Beginning at 6 weeks of age (pre-plaque), TgCRND8 mice were treated with vehicle or SCH 785532 (100 mg/kg/day, in diet) for 6, 12, 18 or 24 weeks (well into the plaque deposition period). This dose given in diet provided relatively constant exposure and robust inhibition of plasma Aβ. Following 12-24 weeks of treatment, SCH 785532 reduced total guanidine extracted cortical Aβ40 and Aβ42 levels by 30%. While total β-amyloid plaque burden was not dramatically changed with SCH 785532 treatment, mature Thioflavine S positive fibrillar Aβ containing plaques were reduced by 35% after 24 weeks of treatment. Increased microglia reactivity observed around Aβ plaques was not noticeably reduced by 24 weeks of treatment with SCH 785532. TgCRND8 mice treated with vehicle did not perform as well as non-transgenic vehicle-treated mice in the Morris water maze and 24 weeks of treatment with SCH 785532 moderately improved performance of the transgenic mice in this cognition model. Overall, the results of this study demonstrate that chronic BACE inhibition reduced brain Aβ levels, delayed the maturation of amyloid plaques, improved cognitive function and was well tolerated. This study provides support that inhibition of BACE may have disease-modifying potential in the clinic.

P3‐299: Chronic Administration of a Novel BACE Inhibitor Reduced Brain Aβ Levels and Mature Plaques and Modestly Improved Cognition in Transgenic CRND8‐APPswe/ind Mice

Discovery of Novel, Potent BACE Inhibitors with Central Activity for the Treatment of Alzheimer's Disease

Targeted BACE-1 inhibition in microglia enhances amyloid clearance and improved cognitive performance

Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease

Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.

BACE Inhibitor Clinical Trials for Alzheimer's Disease

P4-364 Rapid In-Vivo Assessment of Therapeutic Window of Two Γ-Secretase Inhibitors in Transgenic CRND8 Mice

In Vivo Characterization of a Novel -Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects

Beneficial effects of physical exercise and an orally active mGluR2/3 antagonist pro-drug on neurogenesis and behavior in an Alzheimer's amyloidosis model

Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates.

P2‐359: Cathepsin B Gene Deletion or Inhibition Improves Memory Deficits in a Mouse Model of Alzheimer's Disease Expressing APP with the Wild‐type Beta‐secretase Site

Berberine Ameliorates Β-Amyloid Pathology, Gliosis, and Cognitive Impairment in an Alzheimer's Disease Transgenic Mouse Model

Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species

Treatment with 1, 10 Phenanthroline-5-Amine Reduced Amyloid Burden in a Mouse Model of Alzheimer's Disease

A Polyaminobiaryl-Based β-secretase Modulator Alleviates Cognitive Impairments, Amyloid Load, Astrogliosis, and Neuroinflammation in APPSwe/PSEN1ΔE9 Mice Model of Amyloid Pathology

Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits Β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice

Early treatment with an M1 and sigma-1 receptor agonist prevents cognitive decline in a transgenic rat model displaying Alzheimer-like amyloid pathology

Inhibition of Tau aggregation with BSc3094 reduces Tau and decreases cognitive deficits in rTg4510 mice

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects

P2-315: A Novel Biotherapy for the Treatment of Alzheimer's Disease

Early Inhibition of Phosphodiesterase 4B (PDE4B) Instills Cognitive Resilience in APPswe/PS1dE9 Mice